Conclusion
DIFFUSE LARGE B CELL LYMPHOMA
The decitabine‐RDHAP regimen is effective and well tolerated, and is a promising salvage regimen for R/R‐DLBCL.A randomized phase II study of decitabine in combination withrituximab, cisplatin, cytarabine, dexamethasone (RDHAP) in relapsed/refractory diffuse large B cell lymphoma. 
Xiaoshuang Kong and Xudong Zhang contributed equally to the work.